Effectiveness of Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Pain, Duration, and Medication Use during Migraines in Otherwise Healthy Participants—A Double-Blind Randomised Controlled Study
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 80 adults randomised. 61 were analysed for the main outcomes.
- Dose used in the study
- 600 mg of Levagen+ at the start of a migraine. A second dose was allowed after 2 hours.
- Duration
- Single migraine events, observed for up to 8 hours
- What was measured
- Pain on a visual analogue scale, time to resolution, use of rescue medication, adverse events
What the authors reported
The authors reported that more migraine events resolved at 2 hours and at 8 hours in the Levagen+ group than in the placebo group, that pain scores were lower at 1.5 and 4 hours, and that rescue medication was used less often. No adverse events were reported in either group.
Limits of this study
About a quarter of those randomised were not in the main analysis. The authors stated that larger studies are needed and that the effect of dose is unclear. The study was funded by Gencor Pacific, which makes Levagen+. The authors were employed by the contract research company that ran the trial.
Source
Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.